tbuckley/cabot-search huggingface dataset:
Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)
Authors: P. C. Nathan, K. K. Ness, M. M. Hudson, M. Mahoney, J. S. Ford, W. Landier, G. Armstrong, T. Henderson, L. L. Robison, K. C. Oeffinger
Journal: Journal of Clinical Oncology (2009)

CRA6501 Background: Childhood cancer survivors may develop a second malignant neoplasm (SMN) and require surveillance to detect new cancers. Methods: We surveyed survivors and siblings from the CCSS, a cohort study of patients who have survived ≥5 years after a diagnosis of childhood cancer from 1970–86. We assessed compliance with the American Cancer Society's (ACS) guidelines for surveillance mammography, colonoscopy and PAP smears, and compared them to a matched population comparison group drawn from the 2003 National Health Interview Survey. Further, we examined compliance with the Children's Oncology Group (COG) guidelines for more frequent colonoscopy, mammography and skin exams in survivors at high risk for cancers of the colon (≥30 Gy pelvic, abdominal or spinal radiation), breast (≥ 20 Gy breast radiation in females) or skin (any radiation). Proportions screened were compared between groups with adjusted generalized estimating equations or log-binomial regression models. Results: There were 8318 survivors (50.6% male, mean age at interview 31.2 ± 7.3 years), 2661 siblings and 8318 population controls. 141/829 (17.6%), 592/855 (70.4%) and 3362/3690 (92.6%) eligible survivors reported a colonoscopy, mammogram, or PAP smear per ACS guidelines. Survivors were less likely than siblings (odds ratio [OR] 0.30; 95% confidence interval [CI] 0.18–0.49) and population controls (OR 0.63; CI 0.50–0.80) to have a colonoscopy, and less likely than siblings to have a PAP smear (risk ratio [RR] 0.98; CI 0.97–0.99). However, they were more likely than siblings (RR 1.14; CI 1.03–1.27) and population controls (RR 1.05; CI 1.01–1.10) to have a mammogram. Among survivors at increased risk for a SMN, only 92/809 (11.4%) reported a colonoscopy within the COG recommended 5-year period, 164/537 (30.5%) reported a mammogram within a 1-year period and 1288/4833 (26.7%) reported a skin exam. Care at a cancer center was associated with mammography (RR 1.91; 95% CI 1.02–1.27) and skin exam (RR 1.55; 95% CI 1.22–196) in high-risk patients. Conclusions: Childhood cancer survivors are not screened adequately for SMNs. Surveillance is very poor amongst those at highest risk for colon, breast, or skin cancer. Survivors and their physicians need education about the importance of surveillance. No significant financial relationships to disclose.
Genomic landscape of circulating tumor (ct)-DNA alterations in patients with penile cancer.
Authors: Archana Agarwal, Amin Nassar, Rebecca Nagy, Catherine Curran, Sarah Abou Alaiwi, Bradley Alexander McGregor, AmirAli Talasaz, Richard B. Lanman, Guru Sonpavde
Journal: Journal of Clinical Oncology (2019)

e16027 Background: Penile cancer is a rare disease associated with HPV infection and is known to harbor recurrent somatic genomic alterations in the ERBB (HER)-family, CDKN2A, TP53, NOTCH1 and PIK3CA. ctDNA assay allows the noninvasive genomic profiling of malignancies and may assist with understanding molecular evolution of resistance. To our knowledge, the genomic alterations observed in ctDNA for penile cancer have not been described before. We report ctDNA profiling of patients with advanced penile cancer. Methods: Sixteen pts with metastatic penile cancer from multiple institutions in the United States that underwent ctDNA analysis using the Guardant360 platform were eligible. Three patients had at least one serial ctDNA sample. De-identified demographic data were collected. Guardant 360 is CLIA-certified ctDNA panel that assesses single nucleotide variants and copy number alterations in 68 to 73 genes for potentially actionable genomic alterations. Variants seen at least 3 times in the Catalogue of Somatic Mutations in Cancer (COSMIC) database or reported in OncoKB were considered pathogenic. Results: The median age was 64 years (range 40-77). 4 pts (25%) were documented to be post platinum-based chemotherapy. The median number of ctDNA alterations detected per sample was 2 (range 0-6). Overall, genomic alterations were detected in 15/16 patients (94%) across 21 genes (table 1). Alterations were most frequently detected in TP53 (9/16, 56%), CDKN2A (5/16, 31%), TERT promoter (5/16, 31%), PIK3CA (3/16, 19%) and ERBB2 (3/16, 19%). In 3 patients with serial samples, 9 novel pathogenic alterations were detected in the second sample including ATM, CDKN2A, ARID1A, CCND1, CDK6, EGFR, PDGFRA, PIK3CA, and SMAD4. Conclusions: ctDNA alterations in patients with advanced penile cancer were frequently detected with similar prevalences to previously described tumor tissue analyses. New alterations observed on serial ctDNA assays may provide insights regarding tumor biology and inform drug development. [Table: see text]
Walking Home
Authors: James S. Kahn
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
INSURANCE COMPANIES AND TUBERCULOSIS SANATORIA.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessing solid tumor response with and without RECIST.
Authors: Aileen Deng, Benjamin E Leiby, Russell J. Schilder, William Kevin Kelly, Sandeep Deshmukh, Ashwin Reddy Sama
Journal: Journal of Clinical Oncology (2016)

e18157 Background: Response Evaluation Criteria in Solid Tumors (RECIST) has become widely accepted for response evaluation. RECIST remains underutilized in routine clinical practice. We compared tumor response assessment made with and without RECIST. Methods: This study included patients with solid tumors who underwent imaging from 2013 to 2014 at a single academic center. Tumor response was assessed by a radiologist using RECIST (i.e., RECIST report) and without using RECIST (i.e., standard report). An oncologist (Onc) and resident (Res) interpreted tumor response from standard reports as progressive disease (PD), stable disease (SD), partial response (PR) and complete response (CR). Agreement in assessment between RECIST and standard report was determined by percent agreement and Kappa statistic. Results: 292 imaging studies were included. Agreement was similar between RECIST-classified CR, PD and SD and Onc-interpreted standard report. RECIST-classified PD was interpreted by Onc as SD 29% of the time (Table 1). Overall agreement between RECIST and Onc-interpreted standard report was 56% (95% CI: 46-65%) and Kappa was 0.31 (95% CI: 0.19-0.44). Similar results were seen between RECIST-classified PD and SD and Res-interpreted standard report. RECIST-classified PD is interpreted by Res as SD 24% of the time. Overall agreement between RECIST and Res-interpreted report was 54% (95% CI: 44%-63%) and Kappa was 0.26 (95% CI: 0.13-0.40). Conclusions: Our study found variability in tumor response assessment with and without RECIST. RECIST-classified PD was often interpreted as SD and vice versa, a distinction that can affect treatment decisions. Our study highlights the need to standardize tumor response assessment. Agreement between RECIST and standard report (# reports; % agreement). RECIST Oncologist Assessment Resident Assessment Report CR PD PR SD CR PD PR SD Total CR 12 0 0 8 1 0 0 19 20 60% 0% 0% 40% 5% 0% 0% 95% PD 1 54 0 23 0 56 3 19 78 1.3% 69.2% 0% 29.5% 0% 71.8% 3.9% 24.4% PR 2 4 8 40 0 3 15 36 54 3.7% 7.4% 14.8% 74.1% 0% 5.6% 27.8% 66.7% SD 14 27 10 89 0 37 18 85 140 10% 19.3% 7.1% 63.6% 0% 26.4% 12.9% 60.7% Total 29 85 18 160 1 96 36 159 292
EHPnet: Mad Cow Media
Journal: Environmental Health Perspectives (1998)

Forumneutralized the TNF-a protein.The reac- tion of these mice to ozone was similar to that of the resistant mice.Although Kleeberger calls this evidence "intriguing," it is not proof that TNF-a is the controlling gene in ozone susceptibility, he says.More linkage and physical map studies are needed to identify what he suspects may be a bevy of major and contributing genes associated with differing susceptibilities to ozone.Indeed, Aravinda Chakravarti, a professor of genetics and medicine at Case Western Reserve University in Cleveland, Ohio, questions the use of mice as surrogates for how ozone affects human biology.The inbred mice used in the studies surely have less genetic variation in their reaction to ozone than that found in humans, he says, and moreover, humans metabolize oxygen differently.But Kleeberger points out that the "mouse represents a unique model to study genes in their most simple representation."Michael Blaese, chief of the clinical gene therapy branch at the National Human Genome Research Institute in Bethesda, Maryland, says it makes sense that TNF-a may be in some way linked to ozone suscep- tibility because it is involved in so many important biological activities.Even so, Blaese believes that any effort to clinically correct or repair susceptibility genes will be a long time in coming because of the inherent difficulties of gene therapy.More likely, he says, researchers will search for dinical ways to interfere with the protein encoded by the gene.This work offers hope to millions ofasth- matics, says Sharon Hipkins, director of programs and policy at the Asthma and Allergy Foundation ofAmerica in Washington, DC.It highlights "clinical recognition that there probably is a familial trait that mediates reac- tion to high ozone levels and that, likely, many asthmatics are affected," she says.But Kleeberger says that asthma is a very complex disorder with a number of different phenotypes and that the association between ozone and asthma susceptibility is not completely understood."What is most interesting about these
Consent for invasive procedures in the newly deceased
Authors: G. Brattebo
Journal: JAMA (1995)

<h3>In Reply.</h3> —While Dr Marshall correctly points out the morbidity often associated with treatment for localized prostate cancer, he neglects a fundamental finding of our study: general healthrelated quality of life was not discernibly affected in these men, despite the pelvic dysfunctions they may have experienced. Informed decision making and shared responsibility are clearly the best ways for clinicians to guide patients through uncertain clinical choices. But Marshall's suggested informed consent for DRE and PSA testing would heavy-handedly push patients away from prostate evaluation. His detailed description of the risks, with mere lip service paid to the benefits, would be unfair to patients. As anyone who has lost a relative or friend to prostate cancer can attest, this disease can cause great disability, pain, and distress.<sup>1</sup> Our best defense against prostate cancer is probably early diagnosis. Despite a controversial literature, PSA has been proven highly accurate (91% specific and
Oral Pathology
Authors: Daniel M. Laskin
Journal: JAMA (1965)

Representing the contribution of 31 authors, this book covers extensively the developmental, microbial, metabolic, neoplastic, allergic, physical, chemical, and genetic aspects of oral pathology. Additional chapters deal with inflammation and wound healing, oral and facial pain, histochemical technique and biopsy procedure. The section devoted to the clinical and radiographic appearance of oral structures, and conditions that resemble disease processes, will particularly interest the physician. Each pathologic entity is discussed according to its etiology, clinical features, histologic appearance, and treatment. Most chapters contain numerous clinical photographs, radiographs, and photomicrographs. There is also a separate section containing 142 colored illustrations of various oral conditions. Included in the text are many tables which categorize the different diseases, describe their salient features, and list the other conditions which must be considered in differential diagnosis. The few faults that exist do not seriously detract from the overall value of the book, and are mainly a
Massive Hemorrhage from Small Intestinal Intubation Biopsy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Seasonal Changes in Lead Absorption in Laboratory Rats
Authors: James C. Barton, William J. Huster
Journal: Environmental Health Perspectives (1987)

A retrospective study of the relationship of season to the absorption of radiolead in laboratory rats was performed using data representing 305 animals from 36 experiments over 6 calendar years. Male Wistar rats weighing 200 to 250 g were given 1 microgram of radiolabeled lead in an aqueous solution, pH 4.0, in isolated small intestine, and absorption of the radiolead was quantified after a 4-hour interval using whole-body counting. Similar values of absorption occurred in the summer (June-August) and fall (September-November), 20.51 +/- 1.11% (1 SEM) and 23.0 +/- 1.23% of the test dose, respectively, but significantly lower values occurred in the winter (December-February) and spring (March-May): 16.51 +/- 0.77%, p less than 0.01, and 11.87 +/- 0.99%, p less than 0.01, respectively. Harmonic analysis yielded an excellent approximation of the mean quarterly absorption data. The resulting cosine function had a period of 4.08 +/- 0.05 quarter-years with an amplitude of 7.32 +/- 1.06%; predicted peak absorption values fell precisely between summer and fall. The relationships of these observations to possible mechanisms of lead absorption and to summertime epidemics of lead poisoning in children are discussed.
Out of Computer, by Joint
Authors: E. J. H.
Journal: Annals of Internal Medicine (1965)

Editorials1 March 1965Out of Computer, by JointIndex of RheumatologyE. J. H.E. J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-62-3-626 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThrough 30 years the American Rheumatism Association has sponsored the preparation of reviews published in the ANNALSunder the title, in recent years,Rheumatism and Arthritis. The first few reviews in this series, prepared under the direction and inspiration of Dr. Philip S. Hench—Nobel co-laureate with Drs. Kendall and Reichstein for their epochal efforts that introduced the corticosteroids into clinical medicine—handily presented timely distillations of the English literature on joint disease. But these reviews grew in scope and size through the years, and because of their function, in part, as extensively annotated bibliographies, each successive review suffered a longer gestation...References1. RUHLSOKOLOFF MJL: The literature analysis project of the American Rheumatism Association. Arthritis Rheum. 7: 615, 1964. CrossrefMedlineGoogle Scholar2. RUHLSOKOLOFF MJL: A thesaurus of rheumatology. Arthritis Rheum. 8: (Supp.) 95, 1965. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1965Volume 62, Issue 3Page: 626-626KeywordsArthritisComputersDistillationPregnancy ePublished: 1 December 2008 Issue Published: 1 March 1965 PDF downloadLoading ...
Course: Selected Topics in Nuclear Radiology—1988
Journal: JNCI Journal of the National Cancer Institute (1987)

Course: Selected Topics in Nuclear Radiology—1988 Get access JNCI: Journal of the National Cancer Institute, Volume 79, Issue 5, November 1987, Page 1173, https://doi.org/10.1093/jnci/79.5.1173-c Published: 01 November 1987
Entstehung, Erkennung und Behandlung innerer Krankheiten.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"DIVINE HEALING" HOMICIDE
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Role of the TSC1-TSC2 Complex in the Integration of Insulin and Glucose Signaling Involved in Pancreatic β-Cell Proliferation
Authors: Alberto Bartolomé, Carlos Guillén, Manuel Benito
Journal: Endocrine Reviews (2010)

Tuberous sclerosis complex proteins 1-2 (TSC1-TSC2) complex integrates both nutrient and hormonal signaling and is a critical negative regulator of mammalian target of rapamycin (mTOR) complex 1. The use of different β-cell lines expressing or not the insulin receptor (IR+/+ and IR−/−) or with a reconstituted expression of IR isoform A or B (Rec A and Rec B) revealed that both phosphatidylinositol 3-kinase/Akt/TSC/mTOR complex 1 and MAPK kinase/ERK pathways mediate insulin signaling in IR+/+-, IRA-, or IRB-expressing cells. However, glucose signaling was mediated by MAPK kinase/ERK and AMP-activated protein kinase pathways as assessed in IR−/− cells. The effect of insulin on Akt phosphorylation was completely inhibited by the use of the phosphatidylinositol 3-kinase inhibitor wortmannin in IR+/+ and Rec B cells, a partial inhibitory effect being observed in Rec A cell line. The knockdown of TSC2 expression up-regulated the downstream basal phosphorylation of 70-kDa ribosomal protein S6 kinase (p70S6K) and mTOR. More importantly, upregulation of p70S6K signaling impaired insulin-stimulated phosphorylation of Akt Ser473 and p70S6K in IR+/+ and Rec B but not in Rec A cell lines. In fact, insulin receptor substrate-1 Ser307 phosphorylation signal in Rec B was stronger than in Rec A cell line during insulin action. Rec A cells induced a higher proliferation rate compared with Rec B or IR+/+ during serum stimulation. Thus, we propose that the regulation of TSC2 phosphorylation by insulin or glucose independently integrates β-cell proliferation signaling, the relative expression of IRA or IRB isoforms in pancreatic β cells playing a major role.